MY161243A - Fluorinated aminotriazole derivatives - Google Patents
Fluorinated aminotriazole derivativesInfo
- Publication number
- MY161243A MY161243A MYPI2011005927A MYPI2011005927A MY161243A MY 161243 A MY161243 A MY 161243A MY PI2011005927 A MYPI2011005927 A MY PI2011005927A MY PI2011005927 A MYPI2011005927 A MY PI2011005927A MY 161243 A MY161243 A MY 161243A
- Authority
- MY
- Malaysia
- Prior art keywords
- aminotriazole derivatives
- fluorinated aminotriazole
- fluorinated
- derivatives
- formula
- Prior art date
Links
- JSIAIROWMJGMQZ-UHFFFAOYSA-N 2h-triazol-4-amine Chemical class NC1=CNN=N1 JSIAIROWMJGMQZ-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2009052445 | 2009-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY161243A true MY161243A (en) | 2017-04-14 |
Family
ID=42371383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2011005927A MY161243A (en) | 2009-06-09 | 2010-06-07 | Fluorinated aminotriazole derivatives |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8580831B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2440555B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5095035B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101444559B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102414207B (cg-RX-API-DMAC7.html) |
| AR (1) | AR077032A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010258334B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1010738A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2760588C (cg-RX-API-DMAC7.html) |
| CL (1) | CL2011003097A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2587139T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL216792A (cg-RX-API-DMAC7.html) |
| MA (1) | MA33420B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX342440B (cg-RX-API-DMAC7.html) |
| MY (1) | MY161243A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ597453A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2440555T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2544862C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG175363A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI404717B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010143116A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201200127B (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
| RU2492167C2 (ru) | 2007-12-18 | 2013-09-10 | Актелион Фармасьютиклз Лтд | Производные аминотриазола в качестве агонистов alх |
| PT2432760E (pt) | 2009-05-18 | 2013-10-21 | Actelion Pharmaceuticals Ltd | Derivados de espiro [2,4] heptano ligados em ponte como agonistas do receptor fprl2 e/ou receptor alx |
| CN102803237B (zh) | 2009-06-12 | 2014-09-24 | 埃科特莱茵药品有限公司 | 作为alx受体激动剂的噁唑和噻唑衍生物 |
| EP2640699B1 (en) | 2010-11-17 | 2015-10-07 | Actelion Pharmaceuticals Ltd. | Bridged spiro[2,4]heptane ester derivatives |
| TW201305150A (zh) | 2010-12-07 | 2013-02-01 | Actelion Pharmaceuticals Ltd | 作為脂氧素（ａｌｘ）受體激動劑之羥基化胺基三唑衍生物 |
| CA2816376C (en) | 2010-12-07 | 2018-11-20 | Actelion Pharmaceuticals Ltd | Oxazolyl-methylether derivatives as alx receptor agonists |
| MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
| EP2850058B1 (en) | 2012-05-16 | 2016-07-13 | Actelion Pharmaceuticals Ltd. | 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| ES2617863T3 (es) | 2012-06-04 | 2017-06-20 | Actelion Pharmaceuticals Ltd. | Derivados de bencimidazol-prolina |
| SG11201502493XA (en) | 2012-10-10 | 2015-04-29 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives |
| CA2902135A1 (en) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
| JP6366195B2 (ja) | 2013-04-22 | 2018-08-01 | 国立大学法人 東京大学 | 炎症性疾患の予防又は治療剤 |
| AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
| BR112016001106A8 (pt) | 2013-07-18 | 2017-12-26 | Actelion Pharmaceuticals Ltd | Derivados de espiro [2,4] heptano interligados piperazina substituídos como agonistas do receptor de alx |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| ES2696708T3 (es) | 2013-12-04 | 2019-01-17 | Idorsia Pharmaceuticals Ltd | Uso de derivados de bencimidazol-prolina |
| CA3220193A1 (en) | 2021-06-01 | 2022-12-08 | Azcuris Co., Ltd. | Novel oxazole derivative and pharmaceutical composition for preventing or treating allergic diseases comprising the same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62234018A (ja) | 1986-04-02 | 1987-10-14 | Rooto Seiyaku Kk | 糖尿病併発症治療剤 |
| FR2763337B1 (fr) * | 1997-05-13 | 1999-08-20 | Sanofi Sa | Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant |
| KR20030030029A (ko) | 2000-09-22 | 2003-04-16 | 니혼노야쿠가부시키가이샤 | Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법 |
| EP1492552A2 (en) | 2002-04-03 | 2005-01-05 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| CL2003002353A1 (es) * | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| JP2007516434A (ja) | 2003-11-07 | 2007-06-21 | アカディア ファーマシューティカルズ インコーポレイティド | リポキシン受容体ｆｐｒｌ１の、疼痛および炎症の治療に有効な化合物を識別する手段としての使用 |
| BRPI0511510A (pt) * | 2004-05-25 | 2007-12-26 | Metabolex Inc | composto, sais, solvatos, hidratos e pró-drogas farmaceuticamente aceitáveis do mesmo, composição, e, métodos para modular um receptor ativado com proliferador de peroxisoma, para tratar doença, para modular resistência à insulina, para tratar um ou mais fatores de risco para doença cardiovascular, para diminuir nìveis de fibrinogênio, para diminiuir ldlc, para suprimir apetite, e para modular nìveis de leptina em um indivìduo |
| DE602005025655D1 (de) * | 2004-09-17 | 2011-02-10 | Vertex Pharma | Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen |
| US20060293288A1 (en) | 2005-01-07 | 2006-12-28 | Serhan Charles N | Use of resolvins to treat gastrointestinal diseases |
| WO2007055941A2 (en) * | 2005-11-03 | 2007-05-18 | Merck & Co., Inc. | Histone deacetylase inhibitors with aryl-pyrazolyl motifs |
| MX2010001995A (es) | 2007-08-21 | 2010-06-09 | Senomyx Inc | Identificacion de receptores t2r humanos que responden a compuestos amargos que provocan el sabor amargo en composiciones, y uso de los mismos en ensayos para identificar compuestos que inhiben (bloquean) sabor amargo en composiciones y uso de los mi |
| AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
| RU2492167C2 (ru) * | 2007-12-18 | 2013-09-10 | Актелион Фармасьютиклз Лтд | Производные аминотриазола в качестве агонистов alх |
| PT2432760E (pt) | 2009-05-18 | 2013-10-21 | Actelion Pharmaceuticals Ltd | Derivados de espiro [2,4] heptano ligados em ponte como agonistas do receptor fprl2 e/ou receptor alx |
| CN102803237B (zh) | 2009-06-12 | 2014-09-24 | 埃科特莱茵药品有限公司 | 作为alx受体激动剂的噁唑和噻唑衍生物 |
-
2010
- 2010-06-07 WO PCT/IB2010/052509 patent/WO2010143116A1/en not_active Ceased
- 2010-06-07 RU RU2011153772/04A patent/RU2544862C2/ru not_active IP Right Cessation
- 2010-06-07 MY MYPI2011005927A patent/MY161243A/en unknown
- 2010-06-07 KR KR1020127000486A patent/KR101444559B1/ko not_active Expired - Fee Related
- 2010-06-07 EP EP10725500.2A patent/EP2440555B1/en not_active Not-in-force
- 2010-06-07 MX MX2011012739A patent/MX342440B/es active IP Right Grant
- 2010-06-07 MA MA34521A patent/MA33420B1/fr unknown
- 2010-06-07 CN CN201080018293.6A patent/CN102414207B/zh not_active Expired - Fee Related
- 2010-06-07 AU AU2010258334A patent/AU2010258334B2/en not_active Ceased
- 2010-06-07 US US13/376,966 patent/US8580831B2/en not_active Expired - Fee Related
- 2010-06-07 ES ES10725500.2T patent/ES2587139T3/es active Active
- 2010-06-07 SG SG2011078706A patent/SG175363A1/en unknown
- 2010-06-07 CA CA2760588A patent/CA2760588C/en not_active Expired - Fee Related
- 2010-06-07 JP JP2012514570A patent/JP5095035B2/ja not_active Expired - Fee Related
- 2010-06-07 BR BRPI1010738A patent/BRPI1010738A8/pt not_active Application Discontinuation
- 2010-06-07 NZ NZ597453A patent/NZ597453A/xx not_active IP Right Cessation
- 2010-06-07 PL PL10725500.2T patent/PL2440555T3/pl unknown
- 2010-06-08 TW TW099118594A patent/TWI404717B/zh not_active IP Right Cessation
- 2010-06-09 AR ARP100102022A patent/AR077032A1/es unknown
-
2011
- 2011-12-06 IL IL216792A patent/IL216792A/en not_active IP Right Cessation
- 2011-12-07 CL CL2011003097A patent/CL2011003097A1/es unknown
-
2012
- 2012-01-06 ZA ZA2012/00127A patent/ZA201200127B/en unknown
- 2012-08-01 JP JP2012171081A patent/JP5775496B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY161243A (en) | Fluorinated aminotriazole derivatives | |
| MY153985A (en) | Aminotriazole derivatives as alx agonists | |
| MY153921A (en) | Aminopyrazole derivatives | |
| UA102310C2 (ru) | Гетероциклические сульфонамиды, их применение и фармацевтические композиции | |
| MY153617A (en) | Pyridin-4-yl derivatives | |
| MY183312A (en) | Pharmaceutical formulation | |
| WO2009016460A8 (en) | Pyrazole compounds and their use as raf inhibitors | |
| MY150661A (en) | Pyridin-3-yl derivatives as immunomodulating agents | |
| MX2011013771A (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17. | |
| MY170878A (en) | [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 | |
| IN2012DN03182A (cg-RX-API-DMAC7.html) | ||
| MY187718A (en) | Pharmaceutical formulations | |
| WO2008113559A3 (en) | Indolizines and aza-analog derivatives thereof as cns active compounds | |
| MX2011011733A (es) | Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos. | |
| MX2013006420A (es) | Derivados de aminotriazol hidrolixado como agonistas del receptor de alx. | |
| IN2012DN00765A (cg-RX-API-DMAC7.html) | ||
| MX2012001617A (es) | Derivados de 5-fluoro-2-oxopirimidina-1 (2h)-carboxamida substituida-n1. | |
| UA102289C2 (ru) | Гербициды, полученные из циклопентадиона | |
| PH12014501026A1 (en) | [1, 2, 3]triazolo[4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists | |
| MX2013006418A (es) | Derivados de oxazolil-metileter como agonistas del receptor de alx. | |
| IN2012DN00539A (cg-RX-API-DMAC7.html) | ||
| IN2012DN01292A (cg-RX-API-DMAC7.html) | ||
| TN2012000105A1 (en) | Spirolactam derivatives and uses of same | |
| MY161749A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| GEP20156244B (en) | New tertiary 8-hydroxyquinoline-7- carboxamide derivatives and usage thereof |